The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review


Synonyms: docetaxel, EmDOC, CHEMBL92, Taxotere(R), Docetaxel (TN), ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Taxotere

  • Many of the genes shown in this study may contribute to the dual mechanism by which docetaxel inhibits the growth of breast cancer cells at different concentrations [1].
  • TNAs also demonstrated a much longer circulation time in vivo and more drug accumulation in tumor in a murine breast cancer model than Taxotere [2].
  • These findings suggest potential benefit for use of docetaxel and DIM-C-pPhC(6)H(5) combination in lung cancer treatment [3].

Associations of Taxotere with other chemical compounds

  • One of the underlying mechanisms for augmentation of docetaxel-induced apoptosis by celecoxib and ZD1839 is to further inhibit the activation of prosurvival pathway molecules, such as extracellular signal-regulated kinase and AKT, and the promotion of aberrant apoptosis [4].
  • Although no maximum tolerated dose was reached in cycle 1 with 35 mg/m(2) docetaxel, repetitive dosing proved intolerable in a substantial number of patients; thus, the recommended phase II dose of weekly docetaxel is 30 mg/m(2) when combined with 150 mg of daily erlotinib [5].
  • The maximum tolerated dose of every-3-week docetaxel with 10 mg atrasentan is 70 to 75 mg/m(2) [6].
  • The area under the plasma concentration-time curve in patients who received 100 mg oral docetaxel combined with ritonavir simultaneously or ritonavir given 60 minutes before docetaxel was 2.4 +/- 1.5 and 2.8 +/- 1.4 mg/h/L, respectively, compared with 1.9 +/- 0.4 mg/h/L after i.v. docetaxel [7].

Gene context of Taxotere


  1. Molecular profiling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis. Hernández-Vargas, H., Palacios, J., Moreno-Bueno, G. Oncogene (2007) [Pubmed]
  2. Targeted nanoassembly loaded with docetaxel improves intracellular drug delivery and efficacy in murine breast cancer model. Gao, Y., Chen, L., Gu, W., Xi, Y., Lin, L., Li, Y. Mol. Pharm. (2008) [Pubmed]
  3. Enhancement of docetaxel anticancer activity by a novel diindolylmethane compound in human non-small cell lung cancer. Ichite, N., Chougule, M.B., Jackson, T., Fulzele, S.V., Safe, S., Singh, M. Clin. Cancer Res. (2009) [Pubmed]
  4. Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck. Choe, M.S., Chen, Z., Klass, C.M., Zhang, X., Shin, D.M. Clin. Cancer Res. (2007) [Pubmed]
  5. A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies. Chiorean, E.G., Porter, J.M., Foster, A.E., Al Omari, A.S., Yoder, C.A., Fife, K.L., Strother, R.M., Murry, D.J., Yu, M., Jones, D.R., Sweeney, C.J. Clin. Cancer Res. (2008) [Pubmed]
  6. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Armstrong, A.J., Creel, P., Turnbull, J., Moore, C., Jaffe, T.A., Haley, S., Petros, W., Yenser, S., Gockerman, J.P., Sleep, D., Hurwitz, H., George, D.J. Clin. Cancer Res. (2008) [Pubmed]
  7. Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors. Oostendorp, R.L., Huitema, A., Rosing, H., Jansen, R.S., Ter Heine, R., Keessen, M., Beijnen, J.H., Schellens, J.H. Clin. Cancer Res. (2009) [Pubmed]
  8. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. Domingo-Domenech, J., Oliva, C., Rovira, A., Codony-Servat, J., Bosch, M., Filella, X., Montagut, C., Tapia, M., Campás, C., Dang, L., Rolfe, M., Ross, J.S., Gascon, P., Albanell, J., Mellado, B. Clin. Cancer Res. (2006) [Pubmed]
  9. Docetaxel-induced apoptosis of human melanoma is mediated by activation of c-Jun NH2-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 pathway. Mhaidat, N.M., Zhang, X.D., Jiang, C.C., Hersey, P. Clin. Cancer Res. (2007) [Pubmed]
  10. Lack of association of single-nucleotide polymorphisms in pregnane X receptor, hepatic nuclear factor 4alpha, and constitutive androstane receptor with docetaxel pharmacokinetics. Tham, L.S., Holford, N.H., Hor, S.Y., Tan, T., Wang, L., Lim, R.C., Lee, H.S., Lee, S.C., Goh, B.C. Clin. Cancer Res. (2007) [Pubmed]
  11. ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Sissung, T.M., Baum, C.E., Deeken, J., Price, D.K., Aragon-Ching, J., Steinberg, S.M., Dahut, W., Sparreboom, A., Figg, W.D. Clin. Cancer Res. (2008) [Pubmed]
  12. A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers. Baar, J., Silverman, P., Lyons, J., Fu, P., Abdul-Karim, F., Ziats, N., Wasman, J., Hartman, P., Jesberger, J., Dumadag, L., Hohler, E., Leeming, R., Shenk, R., Chen, H., McCrae, K., Dowlati, A., Remick, S.C., Overmoyer, B. Clin. Cancer Res. (2009) [Pubmed]
WikiGenes - Universities